Kyntra Bio Presents Roxadustat-Focused Strategy After Ending FG-3246 Program
- Kyntra Bio terminated FG-3246 and FG-3180 in fourth-quarter 2026 following insufficient efficacy in a planned Phase 2 interim analysis.
- The termination returns FG-3246 rights to Fortis Therapeutics, reducing operating expenses by over $20 million in 2027 and 2028.
- Resources shift to roxadustat for anemia in lower-risk MDS; Phase 3 initiation is expected in first-quarter 2027, contingent on partnership or external financing.
- Royalty restructuring reduced maximum aggregate payment obligations by $60 million, leaving $15 million in future royalty-backed payments.
- Cash runway is expected to extend into 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.